Neeraj K Agrawal1, Rituparna Maiti, D Dash, B L Pandey. 1. Department Of Endocrinology and Metabolism, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India. drnkavns@gmail.com
Abstract
OBJECTIVES:Inflammation and oxidative stress cause genesis and progression of atherosclerosis in diabetes. This study aimed to assess effects of Cilostazol on these factors in hypertensive type 2 diabetic patients. MATERIALS AND METHODS: In randomized, open, add-on preventive controlled clinical trial design, 60 hypertensive type 2 diabetics aged >or=45 years were evaluated clinically and for total leukocyte count, erythrocyte sedimentation rate, serum albumin, serum hsC-reactive protein, plasma malondialdehyde, blood reduced glutathione and HbA1c levels. After informed consent, 30 patients received Cilostazol (100mg) twice daily orally as add-on therapy. At 1 month follow-up, 26 patients in control group and 22 patients in Cilostazol group completed the trial and particular parameters were re-evaluated. RESULTS: The mean age and duration of diabetes were 55+/-7 years and 8+/-6 years, respectively. At follow-up, the Cilostazol group showed significant (p<0.001) decrease in hsC-reactive protein (23.6%), erythrocyte sedimentation rate (38.7%), total leukocyte count (12.6%), plasma malondialdehyde (17.6%), HbA1c (0.17%, p=0.002) and increase in serum albumin (11.9%), blood reduced glutathione (3.5%) from baseline. UKPDS 10 years risk of coronary heart disease decreased by 6% (p=0.002). The control group did not show significant improvement in inflammatory profile, oxidative status and HbA1c. CONCLUSION:Inflammatory and oxidative stress is high in hypertensive type 2 diabetic patients. Cilostazol reduces these factors as well as coronary heart disease risk in diabetes mellitus.
RCT Entities:
OBJECTIVES: Inflammation and oxidative stress cause genesis and progression of atherosclerosis in diabetes. This study aimed to assess effects of Cilostazol on these factors in hypertensive type 2 diabeticpatients. MATERIALS AND METHODS: In randomized, open, add-on preventive controlled clinical trial design, 60 hypertensive type 2 diabetics aged >or=45 years were evaluated clinically and for total leukocyte count, erythrocyte sedimentation rate, serum albumin, serum hsC-reactive protein, plasma malondialdehyde, blood reduced glutathione and HbA1c levels. After informed consent, 30 patients received Cilostazol (100mg) twice daily orally as add-on therapy. At 1 month follow-up, 26 patients in control group and 22 patients in Cilostazol group completed the trial and particular parameters were re-evaluated. RESULTS: The mean age and duration of diabetes were 55+/-7 years and 8+/-6 years, respectively. At follow-up, the Cilostazol group showed significant (p<0.001) decrease in hsC-reactive protein (23.6%), erythrocyte sedimentation rate (38.7%), total leukocyte count (12.6%), plasma malondialdehyde (17.6%), HbA1c (0.17%, p=0.002) and increase in serum albumin (11.9%), blood reduced glutathione (3.5%) from baseline. UKPDS 10 years risk of coronary heart disease decreased by 6% (p=0.002). The control group did not show significant improvement in inflammatory profile, oxidative status and HbA1c. CONCLUSION: Inflammatory and oxidative stress is high in hypertensive type 2 diabeticpatients. Cilostazol reduces these factors as well as coronary heart disease risk in diabetes mellitus.
Authors: Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan Journal: JCI Insight Date: 2018-01-25
Authors: Dove J Keith; Judy A Butler; Brett Bemer; Brian Dixon; Shawn Johnson; Mary Garrard; Daniel L Sudakin; J Mark Christensen; Cliff Pereira; Tory M Hagen Journal: Pharmacol Res Date: 2012-05-16 Impact factor: 7.658
Authors: B J Rawdin; S H Mellon; F S Dhabhar; E S Epel; E Puterman; Y Su; H M Burke; V I Reus; R Rosser; S P Hamilton; J C Nelson; O M Wolkowitz Journal: Brain Behav Immun Date: 2012-11-29 Impact factor: 7.217